Is Aligos Therapeutics, Inc. overvalued or undervalued?

As of 5 August 2021, Aligos Therapeutics, Inc. has moved from a grade of "does not qualify" to "risky," indicating a notable shift in its valuation assessment. The company is currently considered undervalued, particularly given its low Price to Book Value of 0.38 and an EV to EBITDA ratio of 1.07. However, the company is loss-making, reflected in its NA P/E ratio and negative EV to Sales of -27.66, which raises concerns about its financial health.
In comparison to its peers, Aligos Therapeutics shows a more favorable EV to EBIT ratio of 1.05 compared to ASP Isotopes, Inc. at -22.63 and Journey Medical Corp. at -19.56, both of which are also classified as risky. Despite its recent stock performance, which has seen a significant decline of 81.98% year-to-date compared to a modest 2.44% gain in the S&P 500, the company's high ROCE of 478.69% suggests potential for future profitability if it can stabilize its operations.